Peginterferon SA - Beijing Kawin TechnologyAlternative Names: PEG-IFN-SA; Pegylated interferon variant SA - Beijing Kawin Technology; Pegylated Recombinant Consensus Interferon Variant Solution - Beijing Kawin Technology
Latest Information Update: 02 Nov 2015
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antivirals; Interferons
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Hepatitis C
Most Recent Events
- 01 Oct 2012 Phase-II clinical trials in Hepatitis C (Treatment-naive, Combination therapy) in China (SC) (NCT01908335)